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Abstract
Since the publication of a sham-controlled, randomized trial (AIR2) and subsequent
marketing approval by the US Food and Drug Administration, we have significantly
advanced our understanding of bronchial thermoplasty (BT)’s scientific basis, longterm safety, clinical efficacy and cost-effectiveness. In particular, the last 2 years have
witnessed multiple research publications on several of these counts. In this review, we
critically appraise our evolving understanding of BT’s biologic underpinnings and
clinical impact, offer an evidence-based patient workflow guide for the busy pulmonologist and highlight both current challenges as well as potential solutions for the
researcher and the clinician.
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INTRODUCTION
It is estimated that worldwide, asthma affects over
250 million people and is responsible for over 20 million
disability-adjusted life years.1 In the United States,
asthma affects 25 million people, 5%–10% of whom suffer
from severe persistent symptoms and contribute to the
majority of healthcare utilization associated with the disease; exacerbations requiring emergency management
incur three to four times higher cost among patients with
poorly controlled asthma.2–4 In addition to social and
behavioural interventions, various pharmacological therapies are currently available to help manage this disease,
including biological therapies for patients with elevated
markers of type 2 inflammation.5 However, a significant
portion of asthmatics continue to experience uncontrolled symptoms despite maximal pharmacological treatment, with poor inhaler technique (even among adults),
poor affordability of asthma medications and refractory
asthma (even in the face of multiple inhalers and biologic
therapies) being surprisingly common.6–10 Bronchial
thermoplasty (BT) is a non-pharmacological treatment
option for patients with severe refractory asthma. While
initially considered a novel procedure with uncertain
mechanism of action, high rate of postprocedural asthma
exacerbation and questionable long-term benefit, the last
few years have witnessed important research investigating
the long-term efficacy and safety profile of BT. This
state-of-the-art review provides a succinct overview of
720
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BT, including our understanding of its scientific basis
and the most current data on its safety, efficacy and costeffectiveness.

BT PROCEDURE AND ITS MECHANISM OF
ACTION
BT is performed by direct application of radiofrequency
(RF) energy to the mucosa of larger, endoscopically accessible airways distal to the mainstem bronchi (generally
3–10 mm in diameter). BT involves use of standard flexible
bronchoscopy equipment and usual procedural sedation
(i.e., either moderate sedation or general anaesthesia as per
institutional preference).11 The Alair™ Bronchial Thermoplasty System (Boston Scientific, Natick, MA, USA) consists
of a flexible catheter with an expandable electrode array.
This catheter is passed through the flexible bronchoscope’s
working channel and the electrode array, when expanded, is
utilized for the delivery of RF energy via physical contact
with airway walls (Figure 1).12
Each BT session comprises of a series of treatments (termed ‘activations’) targeting overlapping portions of each
airway, beginning distally and moving proximally.13 Three
treatment sessions are scheduled roughly 3 weeks apart,
each treating one out of the right lower lobe, left lower lobe
and both upper lobes.14 The right middle lobe (RML) was
left untreated in clinical trials due to theoretical risk of
obstruction and RML syndrome, but recent data have
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F I G U R E 1 Bronchial thermoplasty:
currently understood mechanisms of action
involving ASM, associated innervation and
distal airway volume. Reproduced with
permission of the ©ERS 2022. European
Respiratory Review 23 (134) 510–518;
https://doi.org/10.1183/09059180.00005114
Published 1 December 2014. ASM, airway
smooth muscle; RF, radiofrequency

suggested that it may be safe to treat it without clearly
impacting either overall safety or overall efficacy.15,16

Structural changes in the airway wall
The mechanism of action by which BT exerts its effects
appears to be complex and multipronged. Multiple studies
have demonstrated significant reduction in airway smooth
muscle (ASM) mass following BT.17–19 BT has also been
shown to decrease type 1 collagen deposition underneath
the basement membrane.20 However, the association of
ASM mass reduction with clinical response as measured by
improvement in Asthma Control Questionnaire (ACQ)
scores is not well established.17 Recent studies involving
ex vivo human lung specimens have utilized computerbased simulation to demonstrate improvement in airflow
through distal small airways brought about by a 75% reduction in larger airway ASM following BT.21 Therefore, conceivably, the downstream effects of ASM reduction may
better correlate with clinical outcomes than an absolute
reduction in ASM mass.

Airway innervation, neuroendocrine apparatus
and cytokine equilibrium
The parasympathetic nervous system plays an important
role in controlling airway tone with stimulation of cholinergic nerves causing bronchoconstriction, bronchial vasodilation and mucus secretion.22 One study involving 15 patients
with severe asthma found significantly fewer autonomic
nerve fibres in both bronchial submucosa and ASM bundles
3 months after BT.18 Notably, this finding was significantly
associated with a decrease in the number of severe exacerbations, suggesting that disruption of autonomic innervation
post-BT may downregulate airway excitability and bring
about clinical benefits. The same study demonstrated a 95%
reduction in neuroendocrine epithelial cells at the 3-month

mark post-BT, a finding that was also reported to corelate
with an improved asthma control among those patients.
Neuroendocrine cells were also decreased in the untreated
middle lobe where the ASM area was unchanged—a finding
that may offer further insights into the clinical significance
of ASM reduction (or lack thereof). Other data, obtained via
endobronchial biopsies and bronchoalveolar lavage from
patients with severe asthma, point to modulation of key
inflammatory cytokines such as transforming growth factorbeta following BT.23

Airway volumes and ventilation
In one study involving subjects with severe asthma, distal
airway volumes measured using HRCT imaging at functional residual capacity (FRC) and total lung capacity (TLC)
were noted to be significantly increased following BT, as
early as at 1 month. These effects were sustained at
12 months. This increase in distal airway volume corelated
well with a significant improvement in symptoms as
assessed by the ACQ score.24 Other studies involving adults
with severe asthma have also demonstrated a significant
improvement in ACQ scores post-BT, which have corelated
with an increase in FRC and TLC coupled with decreased
residual volume and airway resistance, with the greatest benefit observed in patients with more severe baseline obstructive lung disease.25,26
Hyperpolarized 129Xe MRI, which utilizes a gaseous
contrast agent (Xenon-129) to provide direct visualization
of lung airspaces in an MR image, has been used to quantify
regional lung ventilation defects. This correlates well with
spirometry, disease severity and risk of exacerbations in
asthma.27,28 Recent studies utilizing hyperpolarized MRI
have demonstrated a decrease in the ventilation defect percentage and an increase in well-ventilated lung following
BT—a finding that positively corelated with improved
Asthma Control Test (ACT) scores. One randomized trial
involving 30 subjects, published in 2020, demonstrated
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equivalent clinical efficacy at 1 year and a greater than 50%
reduction in short-term adverse events when limiting treatment to a single BT session targeting the six most involved
airways (identified by hyperpolarized MRI as contributing
most to ventilation defects) compared with the standard
three-session BT therapy.29

Novel insights using optical coherence
tomography
Optical coherence tomography, a non-ionizing and highresolution imaging technique utilizing near-infrared light,
has been used to assess airway wall changes following treatment with BT. Previous studies have demonstrated several
changes immediately following BT including bronchial
wall and peribronchial oedema as well as epithelial
sloughing.30–32 Some of these changes were noted in airways
distal to the ones directly treated as well as in the untreated
RML, again suggesting that the effects of BT are not limited
to directly targeted airways.
Altogether, it appears that the clinical effect of BT may
emanate from an improvement in small airways
dysfunction—a multipronged process that is crucial to the
pathophysiology of asthma.33

Relationship with the underlying endotype/
phenotype
In a recent study published in 2021, endobronchial biopsies
performed on 30 adults with severe asthma showed that
BT’s histologic effects varied considerably with the underlying endotype or phenotype.34 Reduction in ASM was the
most prominent among patients with type 2 highinflammation (T2-high), and epithelial cell proliferation was
the most pronounced in patients with non-allergic, noneosinophilic and non-smoking related asthma, whereas
expression of heat shock proteins appeared to vary with
tobacco exposure. All patients demonstrated increased
expression of epithelial cell glucocorticoid receptors. Notably, despite the seemingly different mechanisms of action of
BT across different asthma endotypes/phenotypes, all subgroups in the study demonstrated similar degrees of clinical
improvement as evidenced by mean change in ACT score
(at 3 months post-BT) of >3 (p < 0.001). Other studies have
demonstrated that certain biologic, genetic or clinical features may portend better clinical response to BT, including
higher baseline serum eosinophil counts, higher serum IgE
levels, higher mucosal eosinophil and IL-33-positive cell
counts, atopic asthma, young age and more severe
disease.17,35–40

MAJOR CLINICAL STUDIES
Major clinical studies are listed in Table 1.

AIR (published in 2007)
The AIR (Asthma Intervention Research) study was a clinical trial of 112 patients with moderate to severe asthma who
were randomized to either BT or usual care.41 At 1 year,
exacerbations and improved ACQ and Asthma Quality of
Life Questionnaire (AQLQ) scores were reported in the BT
arm. Although there were no deaths, the BT arm had more
early adverse events, mostly comprising a transient worsening of asthma symptoms soon after undergoing BT. A major
limitation of this study was the lack of a sham control, making placebo effect a distinct possibility.

RISA (published in 2007)
RISA (Research in Severe Asthma) was a clinical trial of
32 adult patients with severe persistent asthma that was
similar in design to the AIR study but involved patients
with greater disease severity.35 Once again, there was an
uptick in asthma exacerbations during the ‘treatment
phase’ (i.e., the first 6 weeks post-BT), although the rate
of adverse events was similar between treatment and control groups during the ensuing 46 weeks. Treated patients
reported several benefits post-BT including decreased use
of short-acting beta-agonist inhalers and improvement in
AQLQ and ACQ scores. Although the reported efficacy
of BT was put in question by the absence of a sham control and a lack of blinding, this study did unequivocally
demonstrate that BT could be performed in patients suffering from severe asthma with an acceptable safety
profile.

AIR2 (published in 2010)
The AIR2 study was designed to address the potential for
placebo effect in the preceding clinical trials.5,36 This was
a multicentre, double-blinded, sham-controlled trial
including 288 adult patients with severe persistent asthma.
Patients randomized to the control arm underwent bronchoscopy with deployment of the Alair catheter in the airways, but without the delivery of RF energy. While both
arms trended towards improvement in AQLQ scores and
the treatment group’s scores were only modestly better
(bringing into question the utility of AQLQ in the presence of a sham control), patients undergoing BT had
much fewer severe exacerbations (32%), emergency
department (ED) visits (84%) and days lost from work/
school during the post-treatment period (weeks 7–52 following BT). As shown in previous studies, however, this
study also showed a transient worsening of asthma symptoms during the ‘treatment period’ (i.e., first 6 weeks
following BT).
While the AIR2 study unequivocally demonstrated
impressive efficacy during the post-treatment period and
avoided the placebo effect through use of double-blinding

Multicentre,
randomized
trial

Multicentre,
randomized
trial

Multicentre,
double-blind,
randomized
trial

Multicentre,
prospective,
observational
study

AIR, 2007
N = 112

RISA, 2007
N = 32

AIR2, 2010
N = 288

PAS2, 2017
N = 190

Design

Summary of landmark trials

Trial, publication
year, subjects
included (N)

TABLE 1

Followed at 6 weeks
following the
completion of BT,
annual visits up to
5 years after the
therapy

6-week treatment period
followed by 46-week
post-treatment period,
assessed at 3, 6, 9 and
12 months

Sham procedure group
compared with BT

First 190 subjects enrolled
in PAS2 compared
with 190 patients from
AIR2 trial

6-week treatment period,
followed by 46-week
post-treatment period
during which ICS and
OCS dose weaned and
stabilized as possible

6–9-week treatment
period, followed by
12-month follow-up
with LABA withdrawn
for 2-week periods at
3, 6 and 9 months

Duration followed

Usual medical
management
compared with BT

Usual medical
management
compared with BT

Study groups

Severe asthma (requiring
ICS > 1000 μg/day
beclomethasone or
equivalent and
LABA > 80 μg/day
salmeterol or
equivalent). LT
modifiers,
omalizumab and OCS
10 mg/day or less
allowed

Proportion of subjects
experiencing severe
exacerbations during
the subsequent
12-month period
(years 2, 3, 4 and 5)
compared to the first
12 months after BT

Difference in AQLQ
scores from baseline to
average of 6, 9 and
12 months and
proportion of groups
with AQLQ score
change of ≥0.5

Severe asthma (requiring
ICS > 1000 μg/day
beclomethasone or
equivalent and
LABA > 100 μg/day
salmeterol or
equivalent). LT
modifiers,
omalizumab and OCS
10 mg/day or less
allowed
Age: 18–65,
FEV1 ≥ 60%
predicted

Age: 18–65,
FEV1 ≥ 60%
predicted

Difference in the rate of
adverse events
(pulmonary and nonpulmonary) between
BT and comparator
group

Rate of mild exacerbation
during periods of
LABA abstinence
compared with
baseline

Primary outcome

Severe persistent asthma
(requiring
ICS > 750 μg/day
fluticasone or
equivalent and
LABA ≥ 100 μg/day
salmeterol or
equivalent with or
without oral
prednisone ≤ 30 mg/
day, LT modifiers or
theophylline)

Moderate to severe
asthma (requiring
ICS ≥ 200 μg/day
beclomethasone
equivalent and
LABA ≥ 100 μg/day
salmeterol equivalent)

Asthma severity and
baseline controller
medications

Age: 18–65,
FEV1 ≥ 50%
predicted

Age: 18–65, FEV1:
60%–85%
predicted

Subject
characteristics

(Continues)

Significantly reduced
proportion of patients
experiencing severe
exacerbation at
3 years of follow-up
compared to prior to
BT. Similar reduction
compared to AIR2
cohort

Significantly greater
change in average
AQLQ score from
baseline in BT arm;
significantly higher
proportion of subjects
achieved AQLQ score
change of ≥0.5 in the
BT arm

No difference in the rate
of adverse events
between BT and usual
management group in
post-treatment period

Reduced mean rate of
mild exacerbations in
the BT group

Results
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Multicentre,
randomized
control trial

TASMA, 2021
N = 40

No significant difference
in proportion
experiencing severe
exacerbations
12 months prior to
BT10+ visit compared
to years 1 and 5 after
BT. 7% of AIR2
participants who
underwent BT
developed
bronchiectasis but
without clinical
symptoms
Significant decrease in
ASM mass in
immediate BT group
compared to no
change in delayed
group following
6 months of standard
care

Proportion of participants
with severe
exacerbation at years 1
and 5 after BT
compared to
12 months prior to
10-year follow-up
visit. Safety endpoint
regarding clinically
significant imaging
changes following BT

Absolute difference in
ASM mass change
following BT in
immediate therapy
group compared to
pre-BT delayed
therapy group

18/56 control/sham
patients received BT
after the initial trials
concluded.
Maintenance OCS use
noted in 3%–5% of
patients and 7%–8%
received biologic
medications

Severe asthma utilizing
WHO or IMI
definition.
OCS < 20 mg/day
allowed

Age: 18–65 years,
FEV1 ≥ 50%
predicted

Followed 6 months after
randomization to
either arm and
6 months after BT
treatment

Immediate BT group
compared to 6-month
delayed treatment
group

Results

Mean age: 54 years.
Mean FEV1
73% predicted

Primary outcome

Historical data from AIR,
RISA and AIR2 used
to follow outcomes
during years 1–5,
outpatient visit at
10 years following BT
procedure

Duration followed

Asthma severity and
baseline controller
medications

Previous participants
enrolled in AIR, RISA
and AIR2 trials
including control and
sham arm subjects

Study groups

Subject
characteristics

Abbreviations: AIR, Asthma Intervention Research; AQLQ, Asthma Quality of Life Questionnaire; ASM, airway smooth muscle; BT, bronchial thermoplasty; FEV1, forced expiratory volume in the first second; ICS, inhaled corticosteroid; IMI,
Innovative Medicines Initiative; LABA, long-acting beta-agonist; LT, leukotriene; OCS, oral corticosteroid; PAS2, Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma; RISA, Research in Severe
Asthma; TASMA, Unravelling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma; WHO, World Health Organization.

International,
multicentre
follow-up
study

BT10+, 2021
N = 192

Design

(Continued)

Trial, publication
year, subjects
included (N)

TABLE 1
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and a sham control, it begged the question of whether these
gains would last beyond 1 year and therefore make the procedure (including the risk of transiently worsened asthma
symptoms) truly worthwhile.

AIR2: 5-year follow-up (published in 2013)
This study exclusively followed up those patients in the
AIR2 cohort, unblinded by now, who underwent BT either
during or after the AIR2 study.42 Compared to each subject’s own baseline (defined as the year immediately preceding BT), rates of severe exacerbation, hospitalization
and ED visits continued to be decreased up to 5 years following BT. An HRCT scan at 5 years post-BT demonstrated no clinically significant structural abnormalities
following BT.

PAS2 (published in 2017 and in 2022)
In 2017, results of the post-market PAS2 (Post-FDA
Approval Clinical Trial Evaluating Bronchial Thermoplasty
in Severe Persistent Asthma) study were published comparing the first 190 subjects enrolled in the PAS2 study at
3 years of follow-up with data on 190 subjects from the
AIR2 trial at the same interval post-BT.43 Of note, participants in the PAS2 study were on average older, had higher
mean BMI, required higher doses of inhaled corticosteroids
and reported higher rates of severe exacerbations and hospitalizations at baseline. While the initial ‘treatment period’
saw a higher rate of exacerbations and ED visits among the
PAS2 cohort, no differences were noted in rates of
respiratory-related adverse events in the subsequent followup period between the PAS2 and AIR2 cohorts. Moreover,
compared to each PAS2 subject’s own baseline, rates of
severe exacerbation, ED visits and hospitalizations were
lower (by 45%, 55% and 40%, respectively) at year 3 following BT. An extended follow-up of the PAS2 cohort demonstrated sustained reduction in these endpoints and
significantly decreased proportion of subjects requiring
maintenance oral corticosteroids at 5 years compared to
baseline.44,45

BT10+ (published in 2021)
The safety and effectiveness of BT after 10 years in patients
with persistent asthma (BT10+) study was published in
2021.46 This was designed as an international, multicentre,
follow-up study of participants originally enrolled in the
AIR, RISA and AIR2 trials who ended up receiving BT
(either as part of the study treatment group or as a crossover
after the completion of the original study) and who had
10 or more years of follow-up since BT.
Participants were followed up for a median of
12.1 years. Improvements in mean AQLQ and ACQ scores
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after BT were sustained beyond 10 years. The healthcare
utilization benefits of BT also continued, with ED visit rates
and hospitalization rates significantly lower compared to
each subject’s own pre-BT baseline (defined as the
12-month period prior to undergoing BT). Among the
AIR2 cohort, who had undergone HRCT imaging at enrolment, six patients (7%) had developed new bronchiectasis
at the BT10+ follow-up visit. Importantly, clinical symptoms of bronchiectasis were not present in any of these
patients, with one patient having moderate bronchiectasis
and five patients having mild bronchiectasis based on computed tomography review.

TASMA (published in 2021)
The TASMA (Unravelling Targets of Therapy in Bronchial
Thermoplasty in Severe Asthma) study was an international,
multicentre, randomized trial designed to assess the effect of
BT on ASM mass in patients with severe asthma.17 Investigators also analysed data for specific patient characteristics
and biomarkers associated with positive response to BT. As
the primary endpoint for this study was ASM mass, an
objective metric, investigators chose not to include sham
treatment protocol for the control group. However, blinding
was used in outcome assessment.
At 6 months, the ‘immediate treatment’ group undergoing BT had 53% reduction in ASM mass and significantly
improved AQLQ and ACQ scores compared to the ‘delayed
control’ group that had received usual medical care thus far.
Subsequently, the delayed control group also underwent BT
and had similar improvements at 6 months. In a pooled
analysis (n = 35), baseline ASM mass was not a predictor of
improved ACQ scores at 6 months but baseline blood eosinophil and total IgE levels were.
The absence of sham treatment raises a question mark
over the utility of patient-reported questionnaires as the primary marker for treatment success, as was done in this
study. The absence of longer term follow-up should also be
borne in mind when drawing conclusions from this study.

COST CONSIDERATIONS
In a budget impact analysis involving the addition of BT to
standard care among severe persistent asthmatics and
omalizumab non-responders, cumulative costs and cost per
patient per year were projected to decrease despite an initial
increase during the first year of treatment with BT.47
According to a base case economic analysis, BT had an
incremental cost-effectiveness ratio of $29,821/qualityadjusted life years at 10 years in patients with severe persistent asthma on high-dose combination inhaler therapy.48
BT has also been studied in models specific to patients with
moderate to severe allergic asthma and shown to be costeffective relative to both omalizumab and standard
therapy.49
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Altogether, BT appears to be a cost-effective option if
peri-procedural costs are outweighed by costs related to hospitalization and ED visits. Further studies are needed in
larger populations of patients before a reliable comparison
can be made. Such a ‘real-world’ economic comparison may
allow both clinicians and policy makers to make informed
decisions regarding the cost-effectiveness of treatment
options for patients with severe persistent asthma.

PATIENT SELECTION INCLUDING SAFETY
CONSIDERATIONS
Historically, clinical practice guidelines from various societies have offered divergent assessments of the evidence
regarding BT and none to date have incorporated the more
recent data published on this topic. After the 2014 European
Respiratory Society (ERS)/American Thoracic Society (ATS)
guidelines had recommended the use of BT in the context of
a registry or a clinical study, the American College of Chest
Physicians (ACCP) published a position statement to recognize the safety and efficacy of BT in appropriately selected
patients, emphasizing that it should not be considered
experimental nor withheld from patients pending additional
research studies. The Global Initiative on Asthma (GINA)
guidelines recommend considering BT as an add-on treatment option at step 5.6
Figure 2 illustrates an evidence-based general approach
towards patient selection and subsequent management.50

All patients under consideration should be thoroughly evaluated to confirm a diagnosis of asthma along with relevant
phenotyping.51 An exclusion of alternate diagnoses should
be performed to prove the existence of severe asthma
despite optimal medical therapy.52 The role of spirometry
in patient selection is less clear. Although the AIR2 shamcontrolled trial only enrolled patients with a forced expiratory volume in the first second (FEV1) ≥60% and the RISA
trial demonstrated 1-year safety of BT among patients with
FEV1 ≥ 50%, several recent observational studies have
demonstrated largely comparable safety of BT among
patients with FEV1 values as low as 30% along with similar
improvements in ACQ scores.18,53–55 A study of 77 consecutive patients included in the Australian Bronchial Thermoplasty Registry, of whom 19 had FEV1 ≤ 40%, showed
significant clinical improvement and acceptable safety profile following BT despite including older patients (age > 65)
and those with higher annual exacerbation rates compared
with cohorts included in the North American studies. Of
note, however, all patients underwent mandatory overnight
hospitalization contrary to the conventional same-day surgery protocol.55

CURRENT CHALLENGES AND POTENTIAL
NEXT STEPS
At present, several challenges remain in terms of our scientific
understanding of BT and its provision to suitable patients

Patient is being considered for BT
by primary referring clinician

Checklist for BT appropriateness
The patient has a documented
diagnosis of asthma
The patient has recent chest imaging
(CXR or CT scan)
The patient is being medically managed
ged
at ≥Step 4 asthma treatment
The patient has severe asthma (per
current ATS/ERS definition)
Check labs: CBC with diff & serum IgE
E
(w/in 3 months)
Comorbidities have been reviewed and
nd
addressed (e.g., GERD)
Medication adherence has been
reviewed
ACT Score ≤19

Does the patient have any of these
contraindications?
<18 years
Current smoker
History of life-threatening asthma
exacerbation in the past 24 months
Already underwent BT in the past
≥3 LRTIs in past 12 months
Pacemaker, implanted defibrillator, or
another implanted electronic device
Uncontrolled, severe sinus disease
Central airway obstruction
High bleeding risk (e.g., INR>1.5)

BT Session 1
Referral to BT pulmonologist
The patient can be referred
in person or via tele
medicine
Copy of patient history, latest
PFTs and imaging to be
included
Patient is explained the
possible benefits, short-term
risks, and long-term
risks/benefits of BT

Not a
suitable BT
candidate

Communication/referral back
to primary clinician

BT Session
BT
Se si
Se
Sessi
sion 2

BT Session 3

YES

NO

Inclusion Criteria
FEV1 ≥50% predicted
TH2 Low (paucigranulocytic)
Declines, fails, or has
contraindication to biologics
in TH2-high and other
relevant forms of asthma
Patient able to travel to
specialty center

Outpatient follow
up with BT
pulmonologist

F I G U R E 2 BT: an evidence-based general approach towards patient selection and subsequent management. ACT, Asthma Control Test; ATS, American
Thoracic Society; BT, bronchial thermoplasty; CBC, complete blood count; CT, computed tomography; CXR, chest x-ray; ERS, European Respiratory Society;
FEV1, forced expiratory volume in the first second; GERD, gastroesophageal reflux disease; INR, international normalized ratio; LRTI, lower respiratory tract
infection; PFT, pulmonary function test
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Current challenges and potential next steps in the scientific understanding and clinical application of BT

Current challenge

Potential solutions(s)

Limited markers of treatment success56

• Ensure patient blinding (sham control) when using patient-reported symptom
questionnaires
• Measure impact on healthcare utilization (such as ED visits, hospitalization rates, etc.)
• Consider functional imaging (CT and MRI) modalities24,27,28,57
• Explore the role of unconventional markers of airflow obstruction (e.g., impulse
oscillometry)

Lack of blinded long-term follow-up beyond 1 year

• Design a clinical trial along the lines of AIR2 with longer follow-up

Frequent worsening of asthma symptoms in the short
term

• Investigate effective ways of reducing this occurrence, for example, a more effective periprocedural steroid regimen (current convention is 5 days of oral steroids starting 3 days
pre-BT)
• Further explore targeted, single-session BT instead of the conventional, three-session BT29

Limited, although encouraging, cost-effectiveness data

• Perform additional economic analyses on a larger scale using real-world data

Limited, although increasing, understanding of the role of
specific asthma endotypes/phenotypes55

• Perform additional studies on a larger scale to include extremes of ages, all endotypes/
phenotypes and clinical variants such as cough-variant and exercise-induced asthma58

Difficulties with insurance coverage even when patients
meet the conventional treatment criteria59

• Relevant professional societies should formulate updated evidence-based clinical practice
guidelines to reflect the changing landscape of clinical evidence over the past few years
since older guidelines had come out
• Engage with insurance companies to educate them about our updated understanding of
BT, including its safety, effectiveness and cost-effectiveness

Absence of direct comparison with novel biologic
therapies60

• Performed randomized trials entailing head-to-head comparison of BT with novel
biologics approved for T2-high asthma

Abbreviations: BT, bronchial thermoplasty; CT, computed tomography; ED, emergency department.

with severe, refractory asthma. These provide unique opportunities for impactful work in this area (Table 2).

CONCLUSION
Since the publication of the AIR2 sham-controlled, randomized trial in 2010 and subsequent approval of BT by the
Food and Drug Administration (FDA) in the same year,
additional data have made it more evident that BT is a useful option for patients suffering from severe persistent
asthma despite optimization of medical therapy. Previous
concerns regarding long-term safety have been largely put to
rest by recently published data showing excellent safety over
10 or more years following BT, but the similarly excellent
long-term effectiveness data are limited by a lack of patient
blinding and control group comparisons beyond 1 year. The
limited economic analyses thus far completed all point to
excellent cost-effectiveness that rivals that of other step
5 therapy options including biologics, but more research is
needed. Our scientific understanding of BT’s mechanism(s)
of action and the scope of its benefit across various asthma
subgroups continues to increase, and thus far BT has
emerged as a powerful, arguably underutilized, tool that can
benefit a broad range of patients with severe asthma.
A U T H O R C O N T R I BU T I O N S
Asad Khan and Majid Shafiq were involved in study conception. Muhammad Daniyal Hashmi, Asad Khan, and Majid
Shafiq participated in literature review, data synthesis, and
manuscript writing.

CONFLICT OF INTEREST
None declared.
OR CI D
Muhammad Daniyal Hashmi https://orcid.org/00000002-2106-5597
Majid Shafiq https://orcid.org/0000-0001-7971-3350
REFERENC ES
1.

2.
3.

4.

5.
6.
7.

8.
9.

10.

Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al.
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of
Disease Study 2019. Lancet. 2020;396(10258):1204–22.
O’Byrne P, Naji N, Gauvreau G. Severe asthma: future treatments.
Clin Exp Allergy. 2012;42(5):706–11.
Weiss KB, Sullivan SD. The health economics of asthma and rhinitis.
I. Assessing the economic impact. J Allergy Clin Immunol. 2001;
107(1):3–8.
Serra-Batlles J, Plaza V, Morej
on E, Comella A, Brugués J. Costs of
asthma according to the degree of severity. Eur Respir J. 1998;12(6):
1322–6.
Thomson NC. Recent developments in bronchial thermoplasty for
severe asthma. J Asthma Allergy. 2019;12:375–87.
Global Initiative for Asthma. Global Strategy for Asthma Management
and Prevention (2021 Update).
Sanchis J, Gich I, Pedersen S, Aerosol Drug Management Improvement Team (ADMIT). Systematic review of errors in inhaler use:
has patient technique improved over time? Chest. 2016;150(2):
394–406.
Braman SS. The global burden of asthma. Chest. 2006;130(1):4S–12S.
Mavissakalian M, Brady S. The current state of biologic therapies for
treatment of refractory asthma. Clin Rev Allergy Immunol. 2020;
59(2):195–207.
George M, Bender B. New insights to improve treatment adherence in
asthma and COPD. Patient Prefer Adherence. 2019;13:1325–34.

HASHMI ET AL.

728

11.

12.

13.

14.

15.

16.
17.

18.

19.

20.

21.

22.

23.

24.

25.
26.

27.

28.

29.

30.

31.

d’Hooghe JN, Eberl S, Annema JT, Bonta PI. Propofol and
remifentanil sedation for bronchial thermoplasty: a prospective cohort
trial. Respiration. 2017;93(1):58–64.
Bonta PI, Chanez P, Annema JT, Shah PL, Niven R. Bronchial thermoplasty in severe asthma: best practice recommendations from an
expert panel. Respiration. 2018;95(5):289–300.
Dombret M-C, Alagha K, Boulet LP, Brillet PY, Joos G, Laviolette M,
et al. Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults. Eur Respir Rev. 2014;
23(134):510–8.
Cox G, Miller JD, McWilliams A, FitzGerald JM, Lam S. Bronchial
thermoplasty for asthma. Am J Respir Crit Care Med. 2006;173(9):
965–9.
O’Reilly A, Lane S. What is the role of bronchial thermoplasty in the
management of severe asthma? Ther Adv Respir Dis. 2018;12:
1753466618792410.
Wiese T, Kondapaneni M. The safety of treating the right middle lobe
with bronchial thermoplasty. Eur Respir J. 2013;42:P2299.
Goorsenberg AW, d’Hooghe JNS, Srikanthan K, Ten Hacken NHT,
Weersink EJM, Roelofs JJTH, et al. Bronchial thermoplasty induced
airway smooth muscle reduction and clinical response in severe
asthma. The TASMA randomized trial. Am J Respir Crit Care Med.
2021;203(2):175–84.
Pretolani M, Bergqvist A, Thabut G, Dombret MC, Knapp D,
Hamidi F, et al. Effectiveness of bronchial thermoplasty in patients
with severe refractory asthma: clinical and histopathologic correlations. J Allergy Clin Immunol. 2017;139(4):1176–85.
Pretolani M, Dombret MC, Thabut G, Knap D, Hamidi F,
Debray MP, et al. Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am J Respir Crit
Care Med. 2014;190(12):1452–4.
Chakir J, Haj-Salem I, Gras D, Joubert P, Beaudoin ÈL, Biardel S,
et al. Effects of bronchial thermoplasty on airway smooth muscle
and collagen deposition in asthma. Ann Am Thorac Soc. 2015;
12(11):1612–8.
Donovan GM, Elliot JG, Green FHY, James AL, Noble PB. Unraveling
a clinical paradox: why does bronchial thermoplasty work in asthma?
Am J Respir Cell Mol Biol. 2018;59(3):355–62.
Van der Velden VH, Hulsmann AR. Autonomic innervation of
human airways: structure, function, and pathophysiology in asthma.
Neuroimmunomodulation. 1999;6(3):145–59.
Denner DR, Doeing DC, Hogarth DK, Dugan K, Naureckas ET,
White SR. Airway inflammation after bronchial thermoplasty for
severe asthma. Ann Am Thorac Soc. 2015;12(9):1302–9.
Langton D, Banks C, Noble PB, Plummer V, Thien F, Donovan GM.
The effect of bronchial thermoplasty on airway volume measured
12 months post-procedure. ERJ Open Res. 2020;6(4):00300-2020.
Langton D, Bennetts K, Noble P, Plummer V, Thien F. Bronchial thermoplasty reduces airway resistance. Respir Res. 2020;21(1):1–8.
Langton D, Ing A, Bennetts K, Wang W, Farah C, Peters M, et al.
Bronchial thermoplasty reduces gas trapping in severe asthma. BMC
Pulm Med. 2018;18(1):1–7.
Altes TA, Mugler JP III, Ruppert K, Tustison NJ, Gersbach J,
Szentpetery S, et al. Clinical correlates of lung ventilation defects in
asthmatic children. J Allergy Clin Immunol. 2016;137(3):789–96.e7.
Mummy DG, Carey KJ, Evans MD, Denlinger LC, Schiebler ML,
Sorkness RL, et al. Ventilation defects on hyperpolarized helium-3
MRI in asthma are predictive of 2-year exacerbation frequency.
J Allergy Clin Immunol. 2020;146(4):831–9.e6.
Hall CS, Quirk JD, Goss CW, Lew D, Kozlowski J, Thomen RP, et al.
Single-session bronchial thermoplasty guided by 129Xe magnetic resonance imaging. A pilot randomized controlled clinical trial.
Am J Respir Crit Care Med. 2020;202(4):524–34.
Kirby M, Ohtani K, Lopez Lisbona RM, Lee AMD, Zhang W, Lane P,
et al. Bronchial thermoplasty in asthma: 2-year follow-up using optical
coherence tomography. Eur Respir J. 2015;46(3):859–62.
Goorsenberg AW, d’Hooghe JNS, de Bruin DM, van den Berk IAH,
Annema JT, Bonta PI. Bronchial thermoplasty-induced acute airway

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

effects assessed with optical coherence tomography in severe asthma.
Respiration. 2018;96(6):564–70.
Vaselli M, Wijsman PC, Willemse J, Goorsenberg AWM, Feroldi F,
d’Hooghe JNS, et al. Polarization sensitive optical coherence tomography for bronchoscopic airway smooth muscle detection in bronchial thermoplasty-treated patients with asthma. Chest. 2021;160(2):
432–5.
van der Wiel E, ten Hacken NHT, Postma DS, van den Berge M.
Small-airways dysfunction associates with respiratory symptoms and
clinical features of asthma: a systematic review. J Allergy Clin
Immunol. 2013;131(3):646–57.
Papakonstantinou E, Koletsa T, Zhou L, Fang L, Roth M,
Karakioulaki M, et al. Bronchial thermoplasty in asthma: an
exploratory histopathological evaluation in distinct asthma
endotypes/phenotypes. Respir Res. 2021;22(1):1–22.
Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA,
Niven RM, et al. Safety and efficacy of bronchial thermoplasty in
symptomatic, severe asthma. Am J Respir Crit Care Med. 2007;
176(12):1185–91.
Castro M, Rubin AS, Laviolette M, Fiterman J, de Andrade Lima M,
Shah PL, et al. Effectiveness and safety of bronchial thermoplasty in
the treatment of severe asthma: a multicenter, randomized, doubleblind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;
181(2):116–24.
Ladjemi MZ, di Candia L, Heddebaut N, Techoueyres C, Airaud E,
Soussan D, et al. Clinical and histopathologic predictors of therapeutic
response to bronchial thermoplasty in severe refractory asthma.
J Allergy Clin Immunol. 2021;148(5):1227–35.e6.
Postigo M, Hall CS, Castro M. Predicting the response to bronchial
thermoplasty: the needier, the better. J Allergy Clin Immunol Pract.
2020;8(4):1261–2.
Sarikonda K, Sheshadri A, Koch T, Kozlowski J, Wilson B,
Schechtman K, et al. Predictors of bronchial thermoplasty response in
patients with severe refractory asthma, in B13. Mechanisms and treatment considerations for severe asthma. Am J Respir Crit Care Med.
2014;189:A2429.
Ano S, Kikuchi N, Matsuyama M, Nakajima M, Kondo Y, Masuda M,
et al. Transcriptome genetic differences between responders and nonresponders before bronchial thermoplasty. J Asthma. 2021;1–11.
https://doi.org/10.1080/02770903.2021.1945088
Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC,
et al. Asthma control during the year after bronchial thermoplasty. N
Engl J Med. 2007;356(13):1327–37.
Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR,
Shah PL, et al. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin
Immunol. 2013;132(6):1295–302.e3.
Chupp G, Laviolette M, Cohn L, McEvoy C, Bansal S, Shifren A, et al.
Long-term outcomes of bronchial thermoplasty in subjects with severe
asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. Eur Respir J. 2017;50(2):1700017.
Chupp G, Kline J, Khatri S, McEvoy C, Shifren A, Bansal S, et al.
Long-term efficacy and safety of bronchial thermoplasty: 5-year
follow-up results from a large-scale prospective study. Chest. 2020;
158(4):A12–6.
Chupp G, Kline JN, Khatri SB, McEvoy C, Silvestri GA, Shifren A,
et al. Bronchial thermoplasty in patients with severe asthma at 5 years:
the PAS2 study. Chest. 2022;161(3):614–28.
Chaudhuri R, Rubin A, Sumino K, Lapa e Silva JR, Niven R,
Siddiqui S, et al. Safety and effectiveness of bronchial thermoplasty
after 10 years in patients with persistent asthma (BT10+): a follow-up
of three randomised controlled trials. Lancet Respir Med. 2021;9(5):
457–66.
Menzella F, Zucchi L, Piro R, Galeone C, Castagnetti C,
Facciolongo N. A budget impact analysis of bronchial thermoplasty
for severe asthma in clinical practice. Adv Ther. 2014;31(7):751–61.
Zein JG, Menegay MC, Singer ME, Erzurum SC, Gildea TR,
Cicenia JC, et al. Cost effectiveness of bronchial thermoplasty in

BRONCHIAL THERMOPLASTY: A REVIEW

49.

50.

51.

52.
53.

54.

55.

patients with severe uncontrolled asthma. J Asthma. 2016;53(2):
194–200.
Zafari Z, Sadatsafavi M, Marra CA, Chen W, FitzGerald JM. Costeffectiveness of bronchial thermoplasty, omalizumab, and standard
therapy for moderate-to-severe allergic asthma. PLoS One. 2016;11(1):
e0146003.
Niven R, Aubier M, Bonta P, Puente-Maestu L, Facciolongo N,
Ryan D. European consensus meeting/statement on bronchial thermoplasty Who? Where? How? Respir Med. 2019;150:161–4.
Tan LD, Yoneda KY, Louie S, Hogarth DK, Castro M. Bronchial thermoplasty: a decade of experience: state of the art. J Allergy Clin
Immunol Pract. 2019;7(1):71–80.
Schoettler N, Strek ME. Recent advances in severe asthma: from phenotypes to personalized medicine. Chest. 2020;157(3):516–28.
Langton D, Ing A, Fielding D, Hersch N, Sha J, Plummer V, et al.
Safety and effectiveness of bronchial thermoplasty when FEV1 is less
than 50%. Chest. 2020;157(3):509–15.
Doeing DC, Mahajan AK, White SR, Naureckas ET, Krishnan JA,
Hogarth DK. Safety and feasibility of bronchial thermoplasty in
asthma patients with very severe fixed airflow obstruction: a case
series. J Asthma. 2013;50(2):215–8.
Langton D, Wang W, Sha J, Ing A, Fielding D, Hersch N, et al.
Predicting the response to bronchial thermoplasty. J Allergy Clin
Immunol Pract. 2020;8(4):1253–60.e2.

729

56.

57.
58.

59.

60.

Thomson NC. Bronchial thermoplasty as a treatment for severe
asthma: controversies, progress and uncertainties. Expert Rev Respir
Med. 2018;12(4):269–82.
Langton D, Noble PB, Donovan GM. Response of individual airways
in vivo to bronchial thermoplasty. J Appl Physiol. 2021;130(4):1205–13.
Guibert N, Guilleminault L, Lepage B, Heluain V, Fumat R,
Dupuis M, et al. Bronchial thermoplasty in patients with dynamic
hyperinflation: results from the proof-of-concept HEAT trial. Eur Respir J. 2021;57(1):2001616.
Mahajan AK, Hogarth DK. Payer coverage for bronchial thermoplasty: shifting the traditional paradigm for refractory asthma therapy.
Chest. 2013;144(3):1051–4.
Menzella F, Fontana M, Galeone C, D’Amato M, Canonica GW,
Ghidoni G, et al. A real-world evaluation of clinical outcomes of biologicals and bronchial thermoplasty for severe refractory asthma
(BIOTERM). J Asthma Allergy. 2021;14:1019–31.

How to cite this article: Hashmi MD, Khan A,
Shafiq M. Bronchial thermoplasty: State of the art.
Respirology. 2022;27(9):720–9. https://doi.org/10.
1111/resp.14312

